FHTXFoghorn Therapeutics Inc.

$330M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+4.4% YoY

Gross Profit

-$12M-145.3% margin

Operating Income

-$19M-226.9% margin

Net Income

-$16M-194.4% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+7.9%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$205M

Total Liabilities

$295M

Stockholders' Equity

-$90M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$8M	+4.4%
Gross Profit	-$12M	$8M	-251.8%
Operating Income	-$19M	-$24M	+22.4%
Net Income	-$16M	-$19M	+17.1%

FHTX Q3 2025 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena